]

TB Alliance at the 2022 Virtual Union Conference

Join TB Alliance at the virtual 53rd Union World Conference on Lung Health, taking place online on 8 - 11 November 2022. Follow our live coverage on Twitter using @TBAlliance and #UnionConf.

EVENTS CALENDAR

THURSDAY, NOVEMBER 3
Partner Event | Working Group on New Drugs Annual Meeting
9:00-12:00 ET | 15:00-18:00 CEST
TB Alliance will be presenting updates to its pipeline at the Stop TB Partnership’s Working Group on New Drugs (WGND) Annual Meeting. The 2021 WGND Annual Meeting offers a neutral platform to all those actively working in TB drug research and development to provide stakeholders a full understanding of the progress, challenges, and critical issues facing the global TB drug pipeline.

For meeting information and registration, please click here.

Add to Calendar


TUESDAY, NOVEMBER 8
Symposium Session | Clinical experience from BPaL operational research in Asia, Africa and EEC
5:00-6:20 ET | 11:00-12:20 CEST | Channel 1
TB Alliance’s Nix-TB and ZeNix trials have shown that the three-drug, all-oral, 6-month BPaL regimen (bedaquiline, pretomanid and linezolid) can significantly improve success rates for highly drug-resistant TB while simplifying treatment. Following WHO guidelines to implement BPaL under operational research conditions in June 2020, at least 12 countries across Africa, Asia and Europe have commenced operational research or similar programmes. Participants of the symposium will learn about preliminary clinical experience of efficacy, safety and management of adverse events in these countries and discuss how clinical trial findings translate into field experience.

Please see the online program for additional details.

Add to Calendar


Satellite Session | Accelerating the development of new TB drugs and regimens
12:15-1:45 ET | 18:15-19:45 CEST | Channel 3
This session will share details on both the PAN-TB and UNITE4TB clinical programs as examples of innovative and collaborative research and development to find new TB regimens. These programs demonstrate a new wave of coordinated clinical research conducted through consortia. Participants of this satellite session will learn about how UNITE4TB and PAN-TB are working on programs to deliver novel Phase 2 clinical trials that will accelerate the development of new TB drugs and regimens. The regimens are designed to have little to no drug resistance and an improved safety and tolerability profile, relative to existing options.

Please see the online program for additional details.

Add to Calendar


THURSDAY, NOVEMBER 10
Symposium Session | Practical considerations for implementing and scaling up a new DR-TB regimen: experience from early BPaL-adopting countries
6:30-7:50 ET | 12:30-13:50 CEST | Channel 4
Following WHO Guidelines to implement the BPaL regimen (bedaquiline, pretomanid and linezolid) under operations research (OR) conditions in June 2020, several countries began implementing the regimen and scaling up access. As a three-drug, all-oral, 6-month treatment, the BPaL regimen simplifies therapy compared to the longer 18-month, 7–9 drug treatments for pre-extensively drug-resistant TB. Implementing BPaL required countries to prepare and execute plans deliberately and systematically. The first OR commenced within 5 months of the WHO guidelines, with several others following shortly thereafter. There are currently more than 12 ORs underway and three countries have developed sufficient experience to begin scaling up the BPaL regimen under OR conditions. Additionally, since 2019, a vast majority of DR-TB caseload in the United States has been treated with BPaL following US FDA approval.

Symposium participants will learn from implementation experience of early BPaL adopters about best practices for rapidly and effectively deploying novel DR-TB regimens. Please see the online program for additional details.

Add to Calendar


Oral Abstract | Tuberculosis sequencing and resistance
9:00-10:20 ET | 15:00-16:20 CEST | Channel 2
This Oral Abstract presentation will review baseline and acquired resistance development in newer drugs for the treatment of tuberculosis, as well as future predictions for drug resistance profiles and the use of artificial intelligence in determining sequencing and drug-susceptibility.

Please see the online program for additional details.

Add to Calendar


FRIDAY, NOVEMBER 11
Community Connect Session | Researchers sharing with communities (part 1): shorter regimens for drug-sensitive TB
9:00-9:45 ET | 15:00-15:45 CEST | Community Connect Channel
This Community Connect session will provide a forum for researchers involved in these phase III studies to share results (RIFASHORT, TRUNCATE-TB) with or prepare members of TB-affected community and civil society groups for forthcoming results (SimpliciTB), and respond to questions. It will offer an opportunity to discuss next steps, both in terms of ensuring that communities are able to (1) access the benefits of scientific progress; and (2) shape the agenda for future research to further optimize TB treatment regimens.

Please see the Community Connect online program for additional details.

Add to Calendar


Events at the 2022 Union Conference



The BENEFIT Kids program is designed to address critical gaps in research and products in order to improve the treatment and prevention for children affected by multidrug-resistant TB. TB Alliance is a partner on the program, which is led by Stellenbosch University and funded by Unitaid.

Updates from BENEFIT Kids will be presented at this year's virtual Union Conference. Find details below.


TUESDAY, NOVEMBER 8
Oral Abstract | Relative bioavailability of delamanid tablets dispersed in water in healthy adult volunteers
7:31-7:39 ET | 13:31-13:39 CEST | Channel 2
This oral abstract presentation will share details on delamanid tablets dispersed in water and will be presented by Yuanxi Zou.


Poster Presentation | Treatment outcomes in young children with RR-TB treated with regimens including bedaquiline and delamanid: a global individual patient data meta-analysis
9:00-9:08 ET | 10:00-15:08 CEST | E-Posters
This poster presentation will share details on TB diagnostics, including drug-resistance determination, technical aspects and new developments. This will be presented by Maria Garcia-Cremades.


Oral Abstract | Predictors of treatment outcomes in children with rifampicin-resistant tuberculosis: a global individual patient data meta-analysis
10:51-10:59 ET | 16:51-16:59 CEST | Channel 3
Tune in to this oral abstract presentation to hear more about clinical trials and operational research for new treatments for TB (for adults and children). This session will be presented by Prof. Tony Garcia-Prats.


THURSDAY, NOVEMBER 10
Late Breaking Oral Abstract | Pharmacokinetics and optimised dosing of novel dispersible and non-dispersible levofloxacin formulations in children
10:35-10:42 ET | 16:35-16:42 CEST | Late Breaker
This late breaking oral abstract presentation will share results on optimised dosing of novel dispersible and non-dispersible levofloxacin formulations in children. This session will be presented by Dr. Louvina van der Laan.